Association between an excess risk of acute kidney injury and concomitant use of ibuprofen and acetaminophen in children, retrospective analysis of a spontaneous reporting system
- 1.6k Downloads
Ibuprofen and acetaminophen are frequently alternated or simultaneously used to treat fever or pain in children, while the evidence for the safety of such a combination is lacking. In this study, we analyzed the association of acute kidney injury (AKI) with ibuprofen, acetaminophen, and the combination of both drugs in children (0–12 years) by using the FDA Adverse Event Reporting System (AERS) database between January 2004 and June 2012.
Adverse event reports in children aged 0 to ≤12 years were included in the study. Cases were defined as reports of AKI according to the Medical Dictionary for Regulatory Activities (MedDRA) terminology, non-cases as all other reports. Exposure categories were divided into three index groups: two groups where ibuprofen or acetaminophen were used in absence of one another and another group where both drugs were used concomitantly. There was also a reference group, in which neither ibuprofen nor acetaminophen was used. These index groups were compared with the reference group using reporting odds ratios (RORs).
In total, 47,803 reports were included in the study. After adjusting for year of reporting, age, and sex, the ROR for an AKI in children who used only ibuprofen or acetaminophen compared with children who used neither ibuprofen nor acetaminophen was 2.14 (95 % CI: 1.59-2.88) and 1.53 (95 % CI: 1.18-1.97), respectively, while the adjusted ROR was 4.01 (95 % CI: 2.96-5.43) when both drugs were concomitantly used.
The results illustrate that the concomitant use of ibuprofen and acetaminophen in children might be associated with increased risk of AKI.
KeywordsIbuprofen Acetaminophen Acute kidney injury Children Drug interactions Pharmacovigilance
Conflict of interest
No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest to declare.
ZY, PJ, HS and JW were all involved in study design, data analysis and interpretation, drafting revision, and approval of the article.
- 7.McIntyre S, Rubenstein R, Gartner J, Gilboa N, Ellis D (1993) Acute flank pain and reversible renal dysfunction associated with nonsteroidal anti-inflammatory drug use. Pediatrics 92:459–460Google Scholar
- 9.FDA US Food and Drug Administration (2013) Adverse Event Reporting System. http://www.fda.gov/cder/aers/default.htm. Accessed 10 April 2013
- 12.Van Puijenbroek EP, Egberts AC, Meyboom RH, Leufkens HG (1999) Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. Br J Clin Pharmacol 47:689–693CrossRefPubMedCentralPubMedGoogle Scholar
- 15.Bate A, Edwards IR (2008) Data mining techniques in pharmacovigilance. In: Hartzema AG, Tilson HH, Chan KA (eds) Pharmacoepidemiology and therapeutic risk management, 1st edn. Harvey Whitney Books Co., CincinnatiGoogle Scholar
- 17.National Collaborating Centre for Women’s and Children’s Health (2007) Feverish illness in children: assessment and initial management in children younger than 5 years. Royal College of Obstetricians and Gynaecologists Press, London, Available from: http://www.nice.org.uk/nicemedia/live/11010/30525/30525.pdf. Accessed 26 April 2012Google Scholar